Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kimura, Tomoki
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma	Completed	3	397	Europe, Canada, Japan, US, RoW	GSK3511294, Depemokimab, Placebo	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	04/24	04/24
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)	Active, not recruiting	3	641	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	05/25	05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25
Kataoka, Kensuke
NCT06332885: Zephyr Valve Japan Post-Marketing Surveillance	Recruiting	N/A	140	Japan	Zephyr Endobronchial Valve	Pulmonx Corporation	Emphysema, COPD, Severe Emphysema	03/27	03/28